Australia, Feb. 12 -- Vertex Pharmaceuticals Inc., owns the trademark (2607743) for 'AMPOVIOS' till Nov. 27, 2035.
Status: registered:
Registered/protected
Classes: 5 [pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders] and 5 [pharmaceutical preparations for the treatment of immune system related diseases and disorders;pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia;pharmaceutical preparations for the treatment of kidney diseases and disorders;pharmaceutical preparations for the treatment of blood diseases and disorders;pharmaceutical preparations for the treatment of inflammation related diseases and disorders;pharmaceutical preparations for the treatment of autoimmune diseases and disorders;pharmaceutical preparations for the treatment of immunoglobulin A nephropathy;pharmaceutical preparations for the treatment of primary membranous nephropathy;pharmaceutical preparations for the treatment of lupus nephritis;pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis;pharmaceutical preparations for the treatment of immune thrombocytopenia;pharmaceutical preparations for the treatment of immune thrombocytopenia purpura;pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia]
Type of Mark: Word
Date of Acceptance: Dec. 4, 2025
Registration Advertised: Feb. 11
For further details contact PHILLIPS ORMONDE FITZPATRICK.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2607743.
Disclaimer: Curated by HT Syndication.
